Back to Journals » Clinical Ophthalmology » Volume 8

Clinical properties of a novel, glistening-free, single-piece, hydrophobic acrylic IOL

Authors Packer M, rajan M, Ligabue E, Heiner P

Received 6 November 2013

Accepted for publication 13 December 2013

Published 21 February 2014 Volume 2014:8 Pages 421—427


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Mark Packer,1 Mohan Rajan,2 Edoardo Ligabue,3 Peter Heiner4

1Oregon Health and Science University, Portland, OR, USA; 2Rajan Eye Care Hospital Pvt Ltd, Chennai, India; 3Ophthalmology Department, Centro Diagnostico Italiano, Milan, Italy; 4Bond University Medical School, Robina, QLD, Australia

Abstract: A new, single-piece, hydrophobic acrylic lens – the first constructed with a lens optic and haptics comprised of a hydroxyethyl methacrylate-polyethylene glycol phenyl ether acrylate–styrene copolymer, cross-linked with ethylene glycol dimethacrylate, and labeled as "glistening-free" – was recently introduced globally. Glistenings have been a significant source of clinical concern with previous hydrophobic lens designs. This new monofocal lens provides enhanced, clear optics for lens-based surgery. The superior optical clarity of this lens is achieved through the elimination of glistenings, enhanced surface durability, high refractive index, a high Abbe number, and an aspheric design. Additionally, the lens design reduces the risk of developing posterior capsule opacification.

Keywords: glistenings, monofocal hydrophobic acrylic, IOL, aspheric

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]